Abstract
The senescence accelerate mouse P8 (SAMP8) is an excellent model of early learning and memory problems. A number of studies have shown that it has cholinergic deficits, oxidative damage, alterations in membrane lipids and circadian rhythm disturbances. The brains of the SAMP8 overproduce amyloid precursor protein (APP), amyloid-beta protein and have an increased physphorylation of tau. An antisense to APP has been developed that reverses the cognitive deficits and oxidative damage. This antisense represents a poten-tial treatment for Alzheimers disease.
Keywords: Antisense, amyloid-beta, SAMP8, oxidative damage, Alzheimer's, blood brain barrier, testosterone, amyloid precursor protein (APP), cognitive deficits
Current Pharmaceutical Design
Title: The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease
Volume: 18 Issue: 8
Author(s): John E. Morley, Susan A. Farr, Vijaya B. Kumar and Harvey J. Armbrecht
Affiliation:
Keywords: Antisense, amyloid-beta, SAMP8, oxidative damage, Alzheimer's, blood brain barrier, testosterone, amyloid precursor protein (APP), cognitive deficits
Abstract: The senescence accelerate mouse P8 (SAMP8) is an excellent model of early learning and memory problems. A number of studies have shown that it has cholinergic deficits, oxidative damage, alterations in membrane lipids and circadian rhythm disturbances. The brains of the SAMP8 overproduce amyloid precursor protein (APP), amyloid-beta protein and have an increased physphorylation of tau. An antisense to APP has been developed that reverses the cognitive deficits and oxidative damage. This antisense represents a poten-tial treatment for Alzheimers disease.
Export Options
About this article
Cite this article as:
E. Morley John, A. Farr Susan, B. Kumar Vijaya and J. Armbrecht Harvey, The SAMP8 Mouse: A Model to Develop Therapeutic Interventions for Alzheimers Disease, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315795
DOI https://dx.doi.org/10.2174/138161212799315795 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anesthesia and Postoperative Cognitive Dysfunction (POCD)
Central Nervous System Agents in Medicinal Chemistry Editorial [Hot Topic:Active and Passive Aβ-Immunotherapy: Preclinical and Clinical Studies and Future Directions: Part I (Guest Editors: Michael G. Agadjanyan and David H. Cribbs)]
CNS & Neurological Disorders - Drug Targets Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy
Current Medicinal Chemistry Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Inflammation in Ischemic Stroke: Mechanisms, Consequences and Possible Drug Targets
CNS & Neurological Disorders - Drug Targets Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
Current Neuropharmacology <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology Statin Therapy and Cognition in Older People: What is the Evidence?
Current Clinical Pharmacology Patent Selections:
Recent Patents on Regenerative Medicine Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Current Pharmaceutical Design Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Insulin and the Brain
Current Diabetes Reviews Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Current Alzheimer Research